Blog Posts

A New Treatment Option for Advanced EGFR-Mutant NSCLC – IASLC

IASLC/X

Jul 20, 2025, 19:20

A New Treatment Option for Advanced EGFR-Mutant NSCLC – IASLC

International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn:

“A new treatment option has entered the landscape for patients with advanced EGFR-mutant NSCLC.

In the latest Lung Cancer Considered, Dr. Narjust Florez sits down with Dr. Jacob Sands to review the FDA approval of datopotamab deruxtecan for patients who have progressed on both EGFR-targeted therapy and platinum-based chemotherapy.

The conversation highlights trial data, patient selection, and what this new approval means for clinical practice.

Listen now.”

More posts featuring IASLC.

cancer datopotamab deruxtecan IASLC International Association for the Study of Lung Cancer Jacob Sands Lung cancer Lung Cancer Considered Narjust Florez NSCLC OncoDaily Oncology

Andrea Necchi: Interim Results of Sunrise4 are Released in The Lancet Oncology

Why Is Financial Wellness Crucial for Physicians and Health Care Professionals?

BOT/BAL Advancements, BATTMAN Trial, FDA Approval Challenges and Key Highlights from Agenus Stakeholder Briefing

10 Leading Experts Join OncoDaily Medical Journal Editorial Team

Top 10 Oncogrants of the Week: Fueling Cancer Research and Innovation